Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zai Lab Ltd ADR (NQ: ZLAB )

26.10 +0.40 (+1.56%)
Streaming Delayed Price Updated: 10:22 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Ltd ADR

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
From Zai Lab
Via Business Wire
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
From Zai Lab Limited
Via Business Wire
Why Zai Lab (ZLAB) Stock Is Trading Higher
Zai Lab shares are trading higher by 4% during Friday's session. The company priced a $200 million public offering. 
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday
Via Benzinga
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Proposed Public Offering of American Depositary Shares
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
From Zai Lab Limited
Via Business Wire
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
From Zai Lab Limited
Via Business Wire
Zai Lab, A Top 6% Stock, Launched To A 16-Month High On Its 'Impressive' Results
The company is working on an antibody drug conjugate, which is like a smart bomb for cancer cells. 
Via Investor's Business Daily
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday
Via Benzinga
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in November and December Investor Conferences
From Zai Lab Limited
Via Business Wire
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
From Zai Lab Limited
Via Business Wire
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
From Zai Lab Limited
Via Business Wire
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
From Zai Lab Limited
Via Business Wire
Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
From Zai Lab Limited
Via Business Wire
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in September Investor Conferences
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Why Is Zynex (ZYXI) Stock Down 24% Today?
Zynex stock is falling on Friday as ZYXI investor react to earnings misses and poor guidance for Q3 and the full year of 2024. 
Via InvestorPlace
Topics Earnings
Exposures Financial
Why Is DexCom (DXCM) Stock Down 38% Today?
DexCom stock is up on Friday as DXCM investors react to the company's latest earnings report and its lackluster 2024 guidance. 
Via InvestorPlace
Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem
A compelling hidden-gem opportunity, Zai Lab’s groundbreaking cancer therapeutic and discounted valuation could drive up ZLAB stock. 
Via InvestorPlace
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via Business Wire
Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
From Zai Lab Limited
Via Business Wire
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
From Zai Lab Limited
Via Business Wire
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.